<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">TERBINAFINE HYDROCHLORIDE <img border="0" src="../images/pr.gif"/></span><br/>(ter-bin'a-feen)<br/><span class="topboxtradename">Lamisil, </span><span class="topboxtradename">Lamisil DermaGel<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antibiotic</span>; <span class="classification">allylamine</span>; <span class="classification">antifungal</span><br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>250 mg tablets; 1% cream; 1.12% gel</p>
<h1><a name="action">Actions</a></h1>
<p>Synthetic antifungal agent that inhibits sterol biosynthesis in fungi and ultimately causes fungal cell death.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Ergosterol, the principal sterol in the fungal cell membrane, becomes depleted and interferes with cell membrane function,
         thus producing the antifungicidal effect.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Topical treatment of superficial mycoses such as interdigital tinea pedis, tinea cruris, and tinea corporis due to <i>Epidermophyton floccosum, Trichophyton mentagrophytes,</i> or <i>T. rubrum;</i> oral treatment of onychomycosis due to tinea unguium.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to terbinafine; lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Pregnancy (category B). Safety and efficacy in children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Tinea Pedis, Tinea Cruris, or Tinea Corporis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Topical</span> Apply q.d. or b.i.d. to affected and immediately surrounding areas until clinical signs and symptoms are significantly improved
               (17 wk)<br/><br/><span class="indicationtitle">Onychomycosis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 250 mg q.d. times 6 wk for fingernails or times 12 wk for toenails<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Topical</span><br/><ul>
<li>Apply externally. Avoid application to mucous membranes and avoid contact with eyes.</li>
<li>Do not use occlusive dressings unless specifically directed to do so by physician.</li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Skin:</span> Pruritus, local burning, dryness, rash, vesiculation, redness, contact dermatitis at application site. <span class="typehead">CNS:</span>
<span class="speceff-common">Headache.</span>
<span class="typehead">GI:</span> Diarrhea, dyspepsia, abdominal pain, liver test abnormalities, liver failure (rare). <span class="typehead">Hematologic:</span> Neutropenia (rare). <span class="typehead">Special Senses:</span> Taste disturbances. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May increase <b>theophylline</b> levels; may decrease <b>cyclosporine</b> levels; <b>rifampin</b> may decrease <b>terbinafine</b> levels. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 70% PO; approximately 3.5% of topical dose is absorbed systemically. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 36 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for and report increased skin irritation.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Learn correct technique for application of cream.</li>
<li>Notify physician if drug causes increased skin irritation or sensitivity.</li>
<li>Be aware that medication must be used for full treatment time to be effective.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>